Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stemedica itMSC for Moderate to Severe COVID-19 ARDS
NCT04780685Phase 2Unknown
- Sponsor
- Stemedica Cell Technologies
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ischemia-tolerant mesenchymal stem cells in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Stemedica Cell Technologies. Status: unknown.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04780685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780685.